Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of intraoperative remimazolam on postoperative delirium in older cancer patients undergoing major oncologic surgery
ChiCTR2600122767Phase 4Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative delirium (POD), post-operative cognitive decline (POCD), preoperative anxiety and 1 more comparing Placebo group (normal saline) with Intervention group (remimazolam) (2 arms). Primary endpoint: Incidence of postoperative delirium within 7 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
postoperative delirium (POD)post-operative cognitive decline (POCD)preoperative anxietyMalignant solid tumor (MST)
Beyond the preview
Go deeper on ChiCTR2600122767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122767.